SCHEMBL5405544

SCHEMBL5405544

Cc1ccc(CC(=O)N2CCC3(CCN(Cc4ccccc4OCC(C)C)C3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 2/20 0.58
KCNH2 Q12809 2/20 0.58
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP2C19 P33261 1/20 0.49
CYP2D6 P10635 12/20 0.48
TSHR P16473 3/20 0.48
CYP1A2 P05177 2/20 0.48
GHSR Q92847 2/20 0.48
CYP3A4 P08684 6/20 0.48
KDM4E B2RXH2 1/20 0.48
ALOX15 P16050 1/20 0.48
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.45
USP2 O75604 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5433618 0.95 CCR8 (0.53) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5399247 0.94 CCR8 (0.60) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5392143 0.92 CCR8 (0.57) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5402919 0.92 CCR8 (0.57) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5401867 0.90 CCR8 (0.55) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5391268 0.90 CCR8 (0.69) CCR8KCNH2MEN1KMT2ACYP2C19
Trifluoroacetic Acid SCHEMBL5433643 0.90 CCR8 (0.55) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5399596 0.89 CCR8 (0.54) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5433688 0.89 KCNH2 (0.54) CCR8KCNH2MEN1KMT2ACYP2C19
SCHEMBL5399989 0.89 CCR8 (0.54) CCR8KCNH2MEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US claimed
JP-2007509141-A 2007-04-12 JP claimed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP claimed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO claimed
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US disclosed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP disclosed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases CCR8, CCR1, CCR10 CCR8 1/4885KCNH2 2793/4885MEN1 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.